Currently out of the existing stock ratings of Jason Mccarthy, 175 are a BUY (84.54%), 29 are a HOLD (14.01%), 3 are a SELL (1.45%).

Jason Mccarthy

Work Performance Price Targets & Ratings Chart

Analyst Jason Mccarthy, employed at MAXIM GROUP, carries an average stock price target met ratio of 34.21% that have a potential upside of 52.95% achieved within 154 days on average.

Jason Mccarthy’s has documented 408 price targets and ratings displayed on 66 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on GILD, Gilead Sciences at 01-May-2024.

Wall Street Analyst Jason Mccarthy

Analyst best performing recommendations are on ANVS (ANNOVIS BIO ).
The best stock recommendation documented was for ANVS (ANNOVIS BIO ) at 5/13/2021. The price target of $45 was fulfilled within 8 days with a profit of $21.72 (93.3%) receiving and performance score of 116.62.

Average potential price target upside

ABEO Abeona Therapeutics ADMA ADMA Biologics ADMP Adamis Pharma AGEN Agenus AMYT Amryt Pharma Holdings Ltd ARTL Artelo Biosciences ATNF 180 Life Sciences Corp ATOS Atossa Genetics BCLI Brainstorm Cell Therapeutics BGNE BeiGene Ltd BLFS BioLife Solutions BLRX BioLineRx Ltd BLUE Bluebird bio BTX Brooklyn Immunotherapeutics CAPR Capricor Therapeutics CFRX ContraFect Corp CHRS Coherus BioSciences CODX Co-Diagnostics ENTX Entera Bio Ltd GILD Gilead Sciences GLMD Galmed Pharmaceuticals Ltd GOVX GeoVax Labs HTBX Heat Biologics . IMMP Immutep Ltd ADR INO Inovio Pharmaceuticals KZIA Kazia Therapeutics Ltd ADR MESO Mesoblast Ltd MTNB Matinas BioPharma Holdings OMER Omeros ONTX Onconova Therapeutics PRTO Proteon Therapeutics SAVA Cassava Sciences SCYX Scynexis SLS Sellas Life Sciences Group TARA Protara Therapeutics TTNP Titan Pharmaceuticals VKTX Viking Therapeutics VRTX Vertex Pharmaceuticals VTGN VistaGen Therapeutics ADIL Adial Pharmaceuticals MNMD Mind Medicine  ACXP Acurx Pharmaceuticals LLC ANVS Annovis Bio  BIOC Biocept CYTH Cyclo Therapeutics DMAC DiaMedica Therapeutics FENC Fennec Pharmaceuticals GLPG Galapagos NV ADR INDP Indaptus Therapeutics KTRA Kintara Therapeutics MNPR Monopar Therapeutics NHWK Nighthawk Biosciences NLSP NLS Pharmaceutics AG NTEC Intec Pharma Ltd PBLA Panbela Therapeutics RDUS Schnitzer Steel Industries RVPH Reviva Pharmaceuticals Holdings . SNPX Synaptogenix UNCY Unicycive Therapeutics BNGO Bionano Genomics PSTV Plus Therapeutics BNOX Bionomics Ltd ADR FEMY Femasys TCON TRACON Pharmaceuticals INVO INVO Bioscience MBRX Moleculin Biotech

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

21

$16.43 (359.52%)

36

1 months 1 days ago

1/4 (25%)

$16.4 (356.52%)

61

Hold

6

$1.43 (31.29%)

5

1 years 7 months 3 days ago

2/3 (66.67%)

$1.85 (44.58%)

257

Buy

2 years 6 months 19 days ago

0/1 (0%)

$332.5 (79.64%)

Buy

75

$70.79 (1681.47%)

50

3 years 7 months 6 days ago

2/3 (66.67%)

$45.92 (117.11%)

101

Buy

22

4 years 1 months 9 days ago

1/3 (33.33%)

$-59.25 (-72.92%)

820

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Jason Mccarthy is most bullish on?

Potential upside of $19.94 has been obtained for GILD (GILEAD SCIENCES)

Which stock is Jason Mccarthy is most reserved on?

Potential downside of $15.86 has been obtained for MBRX (MOLECULIN BIOTECH)

What Year was the first public recommendation made by Jason Mccarthy?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?